|
Server : Apache/2.4.62 System : FreeBSD fbsdweb2.web.rcn.net 14.1-RELEASE FreeBSD 14.1-RELEASE releng/14.1-n267679-10e31f0946d8 GENERIC amd64 User : www ( 80) PHP Version : 8.3.8 Disable Function : NONE Directory : /domains/bluerae/clients/mipi/prototype2/pipeline/ |
Upload File : |
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
<meta name="description" content="Molecular Insight is focused on critical diagnostic and therapeutic needs of the prostate cancer patient." />
<meta name="keywords" content="prostate cancer, prostate cancer detection, prostate cancer treatment, small-molecule, radiotherapy, metastatic prostate cancer" />
<title>Molecular Insight: Diagnostic-Tc 99m rofolastat</title>
<link href="../stylesmenu.css" rel="stylesheet" type="text/css" />
<link href="../styles.css" rel="stylesheet" type="text/css" />
</head>
<body>
<div id="container">
<!-- LEFT CONTAINER - CONTAINS ALL ELEMENTS ON LEFT HALF OF PAGE, EACH POSITIONED ABSOLTELY -->
<div id="leftcontainer">
<div id="logo"><a href="../index.html"><img src="../images/logo.gif" width="241" height="315" alt="Molecult Insight Home" /></a></div>
<div id="mininav"><a href="../about/contact.html">CONTACT US</a> :: <a href="../search/sitemap.html">SITEMAP</a> :: <a href="../search/index.html">SEARCH</a></div>
<div id="pagemenu">
<p class="currentsection">Pipeline</p>
<ul>
<li><a href="../pipeline/index.html">Overview</a></li>
<li><a href="../pipeline/prostate.html">Prostate Cancer</a></li>
<li><a href="../pipeline/diagnostic.html" class="current">Diagnostic</a></li>
<li><a href="../pipeline/therapeutic.html">Therapeutic</a></li>
<li><a href="../pipeline/discovery.html">Discovery</a></li>
<li><a href="../pipeline/presentations.html">Presentations & Publications</a></li>
</ul>
</div>
<div id="photolarge"><img src="images/p_pipeline.jpg" width="241" height="341" alt=" " /></div>
<div id="photosmall"> <img src="images/p2_about.jpg" width="140" height="181" alt=" " /></div>
<div id="contactinfo">
<p class="address">Molecular Insight Pharmaceuticals, Inc.<br />
<a href="http://maps.google.com/maps?q=160+Second+Street,+Cambridge,+MA+02142&oe=utf-8&client=firefox-a&hnear=160+2nd+St,+Cambridge,+Massachusetts+02142&gl=us&t=m&z=16" target="_blank" class="softlink">160 Second Street, Cambridge, MA 02142</a><br />
617.492.5554 tel :: 617.492.5664 fax<br />
<a href="email:[email protected]">[email protected]</a><br />
</p>
</div>
</div><!--close left container-->
<!-- MAIN CONTENT - includes main menu at top -->
<div id="maincontent" >
<div id="mainmenu">
<ul>
<!--<li style="width: 400px;"> </li>-->
<li><a href="../about/index.html">About Us<span class="separator">::</span></a>
<ul>
<li><a href="../about/executive.html">Executive Management</a></li>
<li><a href="../about/board.html">Board of Directors</a></li>
<li><a href="../about/scientific.html">Scientific Advisory Board</a></li>
<li><a href="../about/careers.html">Careers</a></li>
<li><a href="../about/MolecularInsight_FactSheet.pdf">Fact Sheet (PDF)</a></li>
<li><a href="../about/video.html">Corporate Video</a></li>
<li><a href="../about/licensing.html">Licensing</a></li><img src="../images/menu_bottom.png" width="168" height="8" alt=" " class="menubottom" />
</ul>
</li>
<li><a href="../molecular/index.html">Molecular Medicine<span class="separator">::</span></a>
<ul>
<li><a href="../molecular/mip.html">Molecular Imaging <br />Pharmaceuticals</a></li>
<li><a href="../molecular/tr.html">Targeted Radiotherapeutics</a></li>
<li><a href="../molecular/pt.html">Proprietary Technologies</a></li><img src="../images/menu_bottom.png" width="168" height="8" alt=" " class="menubottom" />
</ul></li>
<li><a href="../pipeline/index.html" class="current">Pipeline<span class="separator">::</span></a>
<ul>
<li><a href="../pipeline/prostate.html">Prostate Cancer</a></li>
<li><a href="../pipeline/diagnostic.html">Diagnostic</a></li>
<li><a href="../pipeline/therapeutic.html">Therapeutic</a></li>
<li><a href="../pipeline/discovery.html">Discovery</a></li>
<li><a href="../pipeline/presentations.html">Presentations & Publications</a></li><img src="../images/menu_bottom.png" width="168" height="8" alt=" " class="menubottom" />
</ul></li>
<li><a href="../intheclinic/index.html">In the Clinic<span class="separator">::</span></a></li>
<li><a href="../media/index.html">Media Room</a>
<ul>
<li><a href="../media/releases.html">Press Releases</a></li>
<li><a href="../media/clips.html">Press Clips</a></li>
<li><a href="../media/interviews.html">Interviews</a></li><img src="../images/menu_bottom.png" width="168" height="8" alt=" " class="menubottom" />
</ul>
</li>
</ul>
</div>
<h1 class="pagehead">Diagnostic-Tc 99m rofolastat</h1>
<p><img src="images/chart_diagnostic.gif" width="525" height="387" alt="Rofolastat Chart" /></p>
<h2>Visualizing Disease</h2>
<p>Medical imaging is a non-invasive means of obtaining a picture of the internal structure and workings of the human body. Currently, the most common methods of visualizing disease provide images of anatomy and include Magnetic Resonance Imaging (MRI), fluoroscopy, Computed Axial Tomography (CAT scan or CT scan), 99mTc-MDP Bone Scan, X-ray, and ultrasound. These methods have limited utility in patients at early stages of disease when gross anatomical changes are not yet evident, in patients who have undergone surgical procedures to treat their disease and anatomy is difficult to assess, or in patients who have systemic disease where the precise locations are unknown.</p>
<p>Molecular imaging differs from anatomical medical imaging in that radioactive drugs are used to detect disease through visualization of physiology and biochemistry, enabling physicians better insight into the disease process. This is markedly different from anatomical imaging and has opened up additional applications for detecting the presence, location and quantity of disease throughout the body. Such images provide vital information related to the diagnosis and extent of disease, prognosis and, ultimately, therapeutic management options. </p>
<h2>How it Works</h2>
<p>Molecular imaging radiopharmaceuticals are targeted radioactive substances that facilitate the visualization of subtle changes in biochemical and biological processes associated with disease progression. The expression of distinct proteins of diseased cells offers the opportunity to diagnose and characterize disease by probing the biochemical composition and phenotypic identity of the diseased tissue. </p>
<p>Molecular Insight uses radiolabeled small molecules that recognize specific receptors, enzymes and proteins in the body that are altered during the evolution of disease. After administration to a patient, these molecules circulate in the blood until they find their intended target. The bound radiopharmaceuticals remain at the site of disease, while the rest of the agent clears rapidly from the body. The radioactive portion of the molecule serves as a beacon so that an image may be obtained depicting the disease location and concentration using commonly available nuclear medicine cameras, known as single-photon emission computerized tomography (SPECT) or positron emission tomography (PET) cameras, found in most hospitals throughout the world. Physicians can then use this information to determine the presence and the extent of disease in a patient, resulting in optimal patient and disease management.</p>
<h2>Tc 99m rofolastat</h2>
<p>Rofolastat is Molecular Insight’s molecular imaging radiopharmaceutical product candidate under development for the detection of metastatic prostate cancer. This compound targets the extracellular domain of prostate specific membrane antigen (PSMA), a protein amplified on the surface of >95% of prostate cancer cells and a validated target for the detection of primary and metastatic prostate cancer. Rofolastat is labeled with technetium-99m, an isotope that is widely available, relatively inexpensive, facilitates ease of preparation, and has optimal diagnostic gamma ray energy for nuclear medicine imaging applications. </p>
<p><em>In patients with metastatic prostate cancer, rofolastat rapidly localizes to lesions in lymph nodes and bone on whole-body imaging as early as 1 hour post-injection with the following results: SPECT/CT images demonstrate excellent lesion contrast target-to-background ratios; enlarged and sub-centimeter lymph nodes are clearly visualized as is the diseased prostate gland;</em><em>good correlation is seen with bone scans in most subjects although, in general, more lesions are visualized with rofolastat than with bone scan. </em></p>
<p>Molecular Insight’s Investigational New Drug application for Rofolastat was approved in the second quarter of 2012. The Company plans to initiate a multi-center international Phase 2 clinical trial in high risk prostate cancer patients undergoing prostatectomy. The Phase 2 trial is set to begin in the second quarter of 2012 in the U.S., and in the third quarter 2012 in Europe.</p>
<!-- FOOTER - contained within main content div -->
<div id="footer">
<p>Copyright © 2012 Molecular Insight. All Rights Reserved. :: <a href="../privacy.html">Privacy Policy</a> :: <a href="../terms.html">Terms of Use</a></p>
</div>
</div>
</div><!--close container-->
</body>
</html>